 |
Case Series
Safe and effective use of cabozantinib and nivolumab in stabilizing disease progression of tissue sarcoma after multiple lines of standard therapy
1 Resident Physician, Department of Internal Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
2 Staff Pathologist, Department of Pathology, Brooke Army Medical Center, San Antonio, Texas, USA
3 Fellow Physician, Department of Hematology/Oncology, Brooke Army Medical Center, San Antonio, Texas, USA
4 Staff Hematologist/Oncologist, Department of Hematology/Oncology, Brooke Army Medical Center, San Antonio, Texas, USA
Address correspondence to:
My Linh D Vu
MD, 3551 Roger Brooke Dr, San Antonio, TX 78219,
USA
Message to Corresponding Author
Article ID: 100123Z10KS2023
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Vu MLD, Berman A, Kao E, Stoll K, Lee L. Safe and effective use of cabozantinib and nivolumab in stabilizing disease progression of tissue sarcoma after multiple lines of standard therapy. J Case Rep Images Oncology 2023;9(2):1–6.ABSTRACT
Introduction: Soft-tissue sarcomas (STS) are a rare and varied group of tumors with limited treatment options. In recent years, immune checkpoint inhibitors have demonstrated efficacy in an increasing number of solid tumors. Nivolumab, a PD1-inhibitor, demonstrates improved overall survival (OS) and progression-free survival (PFS) in renal cell carcinoma, melanoma, and gastrointestinal stromal tumor (GIST). The tyrosine kinase inhibitor (TKI), cabozantinib, demonstrates an antitumor effect in osteosarcoma and Ewing sarcoma.
Case Series: Here we describe two patients with recurrent and refractory STS. Both patients failed multiple lines of conventional therapy including neoadjuvant radiation, surgical resection, and palliative chemotherapy before achieving partial response with combination cabozantinib and nivolumab.
Conclusion: These cases demonstrate the safety and efficacy of using combination nivolumab and cabozantinib in treatment of STS warranting further investigation of immunotherapy treatment.
Keywords: Cabozantinib, Immunotherapy, Metastatic sarcoma, Nivolumab
SUPPORTING INFORMATION
Acknowledgments
The views expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the Department of Defense, the Defense Health Agency, or any agencies under the U.S. Government.
Author ContributionsMy Linh D Vu - Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Andrew Berman - Acquisition of data, Drafting the article, Final approval of the version to be published
Erica Kao - Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Kristin Stoll - Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Lauren Lee - Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2023 My Linh D Vu et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
